NPCE highlights RNS system clinical strength and FDA engagement
NPCE says drug-resistant epilepsy remains under-penetrated and points to Project CARE and expanded IGE indications to drive adoption. It also cites strong RNS clinical results and ongoing FDA engagement targeting a potential IGE approval by 2027.